Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Researchers from Mario Negri Institute for Pharmacological Research, Department of Oncology describe findings in angiogenesis
May 21st, 2008
Research findings, 'Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain,' are discussed in a new report. According to a study from Bergamo, Italy, "Thrombospondin-1, an antiangiogenic matricellular protein, binds with high affinity to the angiogenic fibroblast growth factor-2, affecting its bioavailability and activity. The present work aimed at further locating the fibroblast growth factor-2 binding site of thrombospondin-1 and investigating its activity, using recombinant thrombospondin-1 proteins." "Only recombinant constructs containing the thrombospondin-1 type III repeats bound fibroblast growth factor-2,...
Source: Immunotherapy Weekly (2008-05-21)
|
